Treating long QT syndrome
This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.
1. A method for treating long QT syndrome in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of one or more compounds of Formula (1):
or a pharmaceutically acceptable salt form thereof,
wherein:
R 1 is selected from the group consisting of: hydrogen, halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, —O(C 1 -C 6 )alkyl, and —C(O)R 3 ;
R 2 is selected from the group consisting of: hydrogen, (C 1 -C 6 )alkyl, and —O(C 1 -C 6 )alkyl; and
R 3 is selected from the group consisting of: hydrogen and (C 1 -C 6 )alkyl; or a pharmaceutically acceptable salt form thereof.
2. The method of claim 1 , wherein administration of the compound of Formula (I) shortens the myocardial repolarization time in the patient.
3. The method of claim 1 , wherein R 2 is a —O(C 1 -C 6 )alkyl.
4. The method of claim 3 , wherein R 2 is —O(CH 3 ).
5. The method of claim 1 , wherein the compound of Formula (1) is selected from the group consisting of:
or a pharmaceutically acceptable salt form thereof.
6. The method of claim 5 , wherein the compound of Formula (1) is:
or a pharmaceutically acceptable salt form thereof.
7. The method of claim 1 , wherein the patient has long QT syndrome type 2.
8. The method of claim 1 , wherein the long QT syndrome is drug induced long QT syndrome.
9. The method of claim 1 , wherein the administration of the one or more compounds of Formula (1) is acute.
10. The method of claim 1 , wherein the administration of the one or more compounds of Formula (1) is chronic.
11. The method of claim 1 , wherein at least two compounds are administered to the patient.
12. The method of claim 11 , wherein the administration of at least one of the two compounds is acute.
13. The method of claim 11 , wherein the administration of at least one of the two compounds is chronic.
14. The method of claim 1 , wherein the method further comprises administering one or more glucocorticoid steroids, or a pharmaceutically acceptable salt form thereof.
15. The method of claim 14 , wherein the glucocorticoid steroid is selected from the group consisting of: alclomethasone, amicinonide, beclomethasone, betamethasone, budesonide, carbenoxolone, ciclesonide, clobetasole, clobetasone, clocortolone, cloprednol, corticosterone, corticotropin, cortisol, cortisone, cortivazol, deflazacort, descinolone, desonide, dexamethasone, desoxymethasone, diflorasone, difluocortolone, difluprednate, flucloronide, fludrocortisone, fludroxycortide, flumethasone, flunisolide, fluocortin, fluocinonide, fluocinolone, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluprednisolone, flurandrenolide, fluticasone, formocortal, halcinonide, halobetasol, halomethasone, hydrocortisone, medrysone, methylprednisolone, momethasone, nivazol, paramethasone, prednicarbate, prednisolone, prednisone, prednival, prednylidene, rofleponide, ticabesone, tipredane, tralonide, and triamcinolone.
16. The method of claim 15 , wherein the glucocorticoid steroid is selected from the group consisting of: dexamethasone, flurandrenolide, fluocinonide, and fluorometholone.
17. A method for treating long QT syndrome in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of one or more glucocorticoid steroids, or a pharmaceutically acceptable salt form thereof.
18. The method of claim 17 , wherein the patient has long QT syndrome type 2.
19. The method of claim 17 , wherein the long QT syndrome is drug induced long QT syndrome.
20. The method of claim 17 , wherein the administration of the one or more glucocorticoid steroids is acute.
21. The method of claim 17 , wherein the administration of the one or more glucocorticoid steroids is chronic.
22. The method of claim 17 , wherein the glucocorticoid steroid is selected from the group consisting of: alclomethasone, amicinonide, beclomethasone, betamethasone, budesonide carbenoxolone, ciclesonide, clobetasole, clobetasone, clocortolone, cloprednol, corticosterone, corticotropin, cortisol, cortisone, cortivazol, deflazacort, descinolone, desonide, dexamethasone, desoxymethasone, diflorasone, difluocortolone, difluprednate, flucloronide, fludrocortisone, fludroxycortide, flumethasone, flunisolide, fluocortin, fluocinonide, fluocinolone, fluocortolone, fluorometholone, fluperolone, fluprednidene, fluprednisolone, flurandrenolide, fluticasone, formocortal, halcinonide, halobetasol, halomethasone, hydrocortisone, medrysone, methylprednisolone, momethasone, nivazol, paramethasone, prednicarbate, prednisolone, prednisone, prednival, prednylidene, rofleponide, ticabesone, tipredane, tralonide, and triamcinolone.
23. The method of claim 22 , wherein the glucocorticoid steroid is selected from the group consisting of: dexamethasone, flurandrenolide, fluocinonide, and fluorometholone.
24. The method of claim 14 , wherein the method comprises acute administration of the one or more glucocorticoid steroids, or a pharmaceutically acceptable salt form thereof.
25. The method of claim 14 , wherein the method comprises chronic administration of the compound of Formula (1), or a pharmaceutically acceptable salt form thereof.